Tris Pharma
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · New Jersey, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
2031 Us Hwy 130, Monmouth Junction, New ...Phone Number
(732) 940-2800Website
www.trispharma.comRevenue
$90 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
5
6
1
2
1
1
About Tris Pharma
Tris Pharma is a privately owned premier pharmaceutical company focused on commercializing our branded portfolio of differentiated ADHD medications, seeking development and licensing partnerships by leveraging our novel technology platform, and growing our niche generics business.Explore more
Tris Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Tris Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Tris Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Tris Pharma launches new products
Check out if Tris Pharma is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Tris Pharma
Click to see if Tris Pharma had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Tris Pharma recently announced quarterly report
Check if Tris Pharma has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Tris Pharma has new funding data
Recommended Actions
Reach out to Masked Content who joined Tris Pharma as Masked Content
Find 3 more new buyers
Compare Similar Companies to Tris Pharma
Compare insights from companies similar to Tris Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Tris Pharma
$90M
501-1,000
Private
$5M
2000
PC
Peter CianoChief Financial Officer & SVP Corporate Development
Company Profile Activity
Activity Insights
Tris Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Tris Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Tris Pharma.
Tris Pharma financials insights
Gather financial insights about Tris Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$5M
Tris Pharma Tech Stack
A closer look at the technologies used by Tris Pharma
See more technologies
Most Recent Scoops
Open Position
Promotion
Executive Move
Executive Moves, Promotion
Open Position
Open Position
Person-Based
Tris Pharma News & Media
Tris Pharma Announces Presentation on The Complexity and Management of ADHD at Psych Congress Elevate 2026
MONMOUTH JUNCTION, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company advancing transformative targeted CNS therapeutics, today announced its product theater sponsored presentation at Psych Congress Elevate 2026, taking place June 3-6, 2026, at Caesars Palace in Las Vegas, Nevada.Tris Pharma Appoints Jim Potenziano, Ph.D. as Chief Science and Development Officer
This Role Reflects the Company’s Commitment to Integrated Innovation Across Central Nervous System Disorders.Tris Pharma to Showcase Encore Phase 3 Data Supporting Continued Progress in Acute Pain Treatment at ASRA 2026 Meeting in Phoenix
– Encore data to be presented demonstrating that cebranopadol displays significant and sustained pain reduction with a distinguished safety profile following abdominoplasty and bunionectomy –Tris Pharma Announces Positive Debut Data from Phase 3 ALLEVIATE-1 and 2 Trials Evaluating Cebranopadol in Acute Pain at AAPM PainConnect 2026 Annual Meeting
MONMOUTH JUNCTION, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced debut data from its Phase 3 ALLEVIATE-1 and ALLEVIATE-2 studies evaluating the safety and efficacy of cebranopadol, an investigational therapy, for the treatment of moderate-to-severe acute pain in patients following abdominoplasty and bunionectomy surgery, respectively, at the American Academy of Pain Medicine (AAPM) 2026 PainConnect annual meeting.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Tris Pharma
Sign Up For FreeTo access detailed company insights
Tris Pharma is a privately owned premier pharmaceutical company focused on commercializing our branded portfolio of differentiated ADHD medications, seeking development and licensing partnerships by leveraging our novel technology platform, and growing our niche generics business.... Read More
